As intriguing as EV and cannabis penny stocks are, they come with a lot of risk. So what if you could predict the future? Some speculative areas in technology point to a biotech golden age occurring after the pandemic. One of them worth watching is the synthetic biology movement. Their PR feels a bit like this. Dream or future?
What if you could invest in the 2020s in a movement that could be mainstream by the 2040s? Synthetic biology, an emerging field that applies engineering principles to biology, may someday mean we create our foods and other biological materials in a similar way to electronics and mechanical device.
The Synthetic biology market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 30.28 billion by 2027 growing at a CAGR of 23.63% in the above-mentioned forecast period. It’s a bit like investing in autonomous vehicles in the future of the automotive sector.
Synlogic (SYBX) is working at the intersection of biology and engineering, pioneering the application of synthetic biology to design living therapeutics programmed to treat disease in new ways. The stock is worth about $2.00 currently. They have over 80 employees according to their LinkedIn. They are located in Cambridge MA. SYN is another one worth looking into.
Picking the winners in the Synthetic Biology movement is the fun part, but many of them don’t have a stock ticker yet. What we are now witnessing is the golden age startups getting their first taste of VC funding. DTIL is another one to watch.
The IPOs are coming and the next few years will be very exciting. There will be false starts, but when companies like Synlogic finds its bearings, it could be a winner among many others. Their CEO has her work cut out for her with these challenges of early discovery and inevitable trials and errors.
The best answer to which are the top synthetic biology stocks is probably that they don’t exist yet. But keep watching this space. Betting on some kind of synthetic biology ETF would be a good idea in the 2020s.
TWST, Twist Bioscience is a public company based in San Francisco that manufactures synthetic DNA for clients in the biotechnology industry, but at $40.00 it’s by no means a penny stock. AMRS is another one at about $4.00.
Many companies that today we don’t consider as synthetic biology companies are dipping into the new domain. Like 3D printing, synthetic biology and its related manufacturing advances could become significant drivers of the new consumerism.
The most promising vaccine candidate for Covid-19 is MRNA, and it can certainly be considered a synthetic biology pioneer in a sense. After the pandemic, we can expect the biotech golden age to hit a new level of optimism and slowly replace the technology platform craze that has brought us GAFMA type valuations that even now are acqui-binging due to the destruction of the economy and slumping startups.
Also it’s important to note that America’s tech oligarchy (Billionaire class) basically were the earliest investors into these synthetic biology companies.
We can safely conclude that in the 2020s and 2030s synthetic biology companies will disrupt nearly every industry, from agriculture to medicine to cell-based meats. That potential is worth investing in even for the lowly pandemic day trader.
At the Last Futurist, we are committed to finding startups with valuations that put them within the penny stock range. When you think about the future penny stocks that could one day become the next big thing, also research the key investors who started the movement, this will help you connect the dots.
If you thought ESG stocks were fun to invest in, synthetic biology takes sustainability to a whole different level. Companies like Ginko Bioworks essentially create a monopoly on entire new ecosystems of biotechnology.
Understanding how transhumanists evolve in business settings to get into venture capital can help one get an understanding of the roots of different companies and their future trajectory.